REG - Life Science REIT - Appointment of Non-Executive Director

Life Science ReitAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251203:nRSC9709Ja&default-theme=true

RNS Number : 9709J  Life Science REIT PLC  03 December 2025

3 December 2025

 

Life Science REIT plc

(the "Company" or "LABS")

Appointment of Non-Executive Director

The Board of LABS today announces the appointment of Robert Naylor as the
Senior Independent Non-Executive Director of the Company with immediate
effect.  Robert will replace Richard Howell as Senior Independent
Non-Executive Director, who will continue in his role as a Non-Executive
Director and Chair of the Audit Committee.

Robert has 29 years' experience in capital markets, specialising in the
investment companies' sector. Robert is currently lead fund manager at
Achilles Investment Company Limited, Non-Executive Chair of Aquila European
Renewables plc (a closed-ended investment company specialising in renewable
energy infrastructure), Non-Executive Director of PRS REIT plc, (a FTSE 250
closed-ended real estate investment company, which is in the process of being
sold), Non-Executive Director of NIOX Group PLC (a company dedicated to
improving asthma diagnosis and management) and Non-Executive Director of
Renalytix plc (a precision medicine diagnostics company).

Previously, Robert was Non-Executive Chair of Hipgnosis Songs Fund Limited (a
FTSE 250 closed-ended royalty investment company) and Non-Executive Chair of
Round Hill Music Royalty Fund Limited.  Earlier in his career, Robert held
various positions within JP Morgan Asset Management Limited, Panmure Gordon
(UK) Limited and Cenkos Securities plc. Robert is a qualified chartered
accountant, having started his career with Ernst & Young in 1996.

The following information is disclosed in accordance with UK Listing Rule
6.4.8 in connection with the appointment of Robert Naylor to the Board of the
Company:

 Current Directorship            Previous Directorships in the past five years
 Aquila European Renewables plc  Intuitive Investments Group Plc
 PRS REIT plc                    Round Hill Music Royalty Fund Limited
 NIOX Group Plc                  Light Science Technologies Holdings plc
 Renalytix plc                   Hipgnosis Songs Fund Limited

In addition to the above, Achilles Investment Company Limited hold 13,000,000
ordinary shares in the Company.

There are no additional matters that would require disclosure under UKLR 6.4.8
in respect of Robert Naylor.

FOR FURTHER INFORMATION, PLEASE CONTACT:

 Life Science REIT plc

 Claire Boyle, Chair                                         via Panmure Liberum

 Panmure Liberum - Financial Adviser & Corporate Broker      +44 20 7886 2500

 Tom Scrivens / Chris Clarke / Alex Collins / Ashwin Kohli

 

The Company's LEI is 213800RG7JNX7K8F7525.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLLLBELLXFBE



            Copyright 2019 Regulatory News Service, all rights reserved